Short answer
UroGen Pharma Ltd. (URGN) filed an 8-K current report with the SEC on August 20, 2026 reporting Item 8.01 (Other Events). Exclusive worldwide option for TumoCure and additional SRGel-based products expands UroGen’s oncology pipeline.
UroGen Pharma Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Exclusive worldwide option for TumoCure and additional SRGel-based products expands UroGen’s oncology pipeline
- SRGel platform targets sustained-release delivery, potentially complementing UroGen’s drug-delivery expertise
- Up to $7 million equity investment in IntraGel creates direct financial exposure before license decisions
- Options preserve flexibility while enabling research and evaluation of IntraGel’s platform
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UroGen Pharma Ltd. 8-K filings
Get the next URGN 8-K as it lands
Follow URGN for push alerts, or ask the research agent what this filing means.